By Lynda Searby, 08-Jul-2016
Development of an in vitro model that mimics the gastrointestinal tract is one of the ways in which Biofortis and Triskelion hope to help further research into the relationship between the gut microbiome and immune health, under a new partnership.
In March 2016 the 20th anniversary edition of ChemCon was held in Amsterdam, The Netherlands. Triskelion B.V. was well represented during this event with a stand and 2 presentations on the conference program. Selma Dieperink-Hertsenberg presented a proactive approach ‘How to prepare for REACH evaluation’, related to data availability and quality of REACH registrations. Koen Weel gave an overview of global food contact regulations. A video summarizing his presentation is now available on YouTube.
To meet the rapidly growing global demand for protein, alternative protein sources are needed. For all protein sources it is necessary to know the quality of the protein we consume. FAO (2013) states that the preferred approach to measure protein quality is based on the DIAAS. This score determines which amino acid limits optimal growth and health, and at what level. However, FAO directs that the DIAAS should be investigated in humans or otherwise in pigs: expensive methods with ethical constraints. Is there an in vitro alternative?
To fulfill the demand for higher sensitivity and smaller sample size in bioanalysis, Triskelion is continuously working on the miniaturization of its methodologies. With regard to sample size, Triskelion typically applies 10 µl or 25 µl load volume of biological matrix after extensive optimization of the several sample preparation steps, which is sufficiently low for many bioanalytical applications.